What is Xellar?
Xellar Biosystems operates at the vanguard of the biotechnology sector, defining itself as a Wet Artificial Intelligence company. By synthesizing machine learning algorithms with high-throughput wet-lab experimentation, the firm addresses the inherent complexities of human biology that traditional models often fail to capture. Their core innovation, the Pharma-Scale Organ-on-Chip platform, utilizes image-based AI to provide pharmaceutical researchers with more accurate, predictive data. This approach effectively bridges the gap between theoretical computational models and physical biological reality, positioning Xellar as a critical partner for enterprises seeking to optimize their drug development pipelines and reduce the high failure rates associated with conventional discovery methodologies.
How much funding has Xellar raised?
Xellar has raised a total of $50M across 1 funding round:
Series A
$50M
Series A (2026): $50M, investors not publicly disclosed
Key Investors in Xellar
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Xellar?
With this major enterprise-level funding now secured, Xellar Biosystems is well-positioned to accelerate its research and development initiatives. The strategic roadmap likely involves scaling the production of its Organ-on-Chip systems and deepening its integration with global pharmaceutical partners. By leveraging this capital, the company aims to refine its AI models through increased data acquisition, ultimately shortening the time-to-market for novel therapeutics. As the industry shifts toward more sophisticated, data-driven discovery, Xellar is poised to capture significant market share by providing the infrastructure necessary for the next generation of precision medicine.
See full Xellar company page
